Building Packaging Requirements for IATA Compliance for Regulatory Compliance

Introduction: Why IATA Compliance Matters in Clinical Trial Packaging

Clinical trial samples, especially those containing biological substances, must be packaged in accordance with the International Air Transport Association (IATA) Dangerous Goods Regulations (DGR). Non-compliance can lead to sample rejection, customs delays, or regulatory inspection findings.

Both the FDA and EMA expect sponsors and sites to adopt validated packaging procedures that align with IATA Packing Instructions (e.g., PI650 and PI602), particularly for infectious or diagnostic substances. This article outlines how to develop packaging requirements that are IATA-compliant, audit-proof, and aligned with global GCP expectations.

IATA Packaging Classifications for Clinical Samples

IATA categorizes clinical samples under:

• UN3373 – Biological Substance, Category B: Most diagnostic samples fall under this category and require Packing Instruction 650 (PI650)
• UN2814 or UN2900 – Category A Substances: Infectious substances that require Packing Instruction 602 (PI602)
• Exempt Human/Animal Specimens: Require basic leak-proof packaging but minimal labeling

Triple Packaging System: The Standard for PI650 Compliance

IATA mandates a triple packaging system for UN3373 shipments:

• Primary Receptacle: Leak-proof tube or vial with appropriate volume limits
• Secondary Packaging: Leak-proof, sealed container with sufficient absorbent material
• Outer Packaging: Rigid, durable box capable of protecting the contents during transit

Table: IATA PI650 Key Packaging Requirements

SOP Essentials for IATA-Compliant Packaging

Your SOP must cover:

• Classification of samples (Category A vs. B vs. Exempt)
• Selection criteria for validated packaging vendors
• Instruction on triple packaging assembly
• Labeling requirements, including IATA labels and hazard statements
• Documentation requirements (e.g., Shipper’s Declaration, manifest)
• Training and certification of site staff or couriers handling packaging

Case Study: FDA 483 Observation Due to Packaging Deficiency

During an FDA inspection of a U.S.-based oncology trial, a 483 was issued because samples were shipped in single-layer plastic containers without absorbent material. The outer packaging was not tested for integrity and failed during transport, resulting in a spill and customs seizure.

CAPA Measures Implemented:

• Revised SOP to mandate use of PI650-compliant triple packaging
• Site-level re-training and qualification on packaging assembly
• Implementation of packaging inspection checklist prior to courier handoff

Validation and Documentation of Packaging

Sponsors must ensure that all packaging systems used have been:

• Pre-qualified through validation testing including drop, leak, and pressure resistance
• Documented with Certificate of Conformance (CoC) from vendors
• Inspected at the site prior to dispatch
• Retained as part of the clinical trial master file (CTMF)

Training and Inspection Readiness

Staff involved in sample packaging must complete IATA Dangerous Goods training, valid for two years. Inspection readiness measures include:

• On-site visual verification of packaging materials and labeling
• Review of recent sample shipment records for adherence to SOPs
• Availability of vendor qualifications and training logs
• Corrective action documentation for any previous transport deviations

External Reference

For IATA’s official regulations and training modules, refer to IATA Dangerous Goods Regulations.

Conclusion

IATA-compliant packaging is a non-negotiable element of regulatory compliance in global clinical trials. From packaging material selection to staff training and SOP development, every aspect must be aligned with international standards and national regulations. Proactively building and validating your packaging system not only protects your samples but also ensures smooth inspections and uninterrupted trial progress.

Achieving Sample Collection Kits and Logistics Under FDA and EMA Oversight

Introduction

Effective management of clinical trial sample collection kits and associated logistics is a critical element of compliance, especially in global studies under FDA and EMA oversight. These kits are the primary tools enabling the standardized and protocol-aligned collection, labeling, and shipment of clinical biospecimens such as blood, plasma, serum, urine, or tumor tissue. A failure in kit accuracy, delivery, or tracking can result in sample loss, data invalidation, or regulatory findings.

This tutorial article provides best practices for designing, assembling, deploying, and tracking clinical sample collection kits—alongside CAPA strategies and logistics planning across diverse geographies.

Essential Elements of Sample Collection Kits

According to FDA 21 CFR 312 and EMA GCP Inspection Guidelines, each kit must be tailored to the trial’s protocol and regulatory needs. A sample collection kit typically includes:

• Pre-labelled collection tubes (e.g., EDTA, Heparin, SST)
• Specimen bags with absorbent material
• Barcode labels and chain-of-custody forms
• Dry ice or cold packs (where applicable)
• Detailed collection and packaging instructions
• Shipping documents compliant with IATA and local regulations
• Return containers with pre-printed logistics waybills

All components must be validated for performance and documented in the TMF. Expiry tracking of kit materials (e.g., anticoagulant tubes) is a regulatory requirement.

Regulatory Expectations for Sample Logistics

Both the FDA and EMA emphasize logistics transparency and traceability. Key requirements include:

• Tracking: Real-time tracking of kit delivery and return shipment status
• Temperature Control: Compliance with temperature excursion logs for cold chain shipments
• Courier Qualification: Demonstrated courier SOPs and validation records (e.g., DHL, Marken, World Courier)
• Kit Reconciliation: Confirmation of kit receipt at sites and laboratory
• Deviation Documentation: SOP-defined process to log damaged, incomplete, or delayed kits

Case Study: EMA Inspection Findings – Incomplete Sample Kits in Oncology Trial

In a multicenter oncology study, the sponsor received an EMA GCP inspection finding due to repeated reports of missing materials in kits (e.g., tubes without labels, incomplete shipping documents). This led to protocol deviations and loss of valuable biospecimens.

CAPA Implemented:

• Kit assembly moved to a centralized GMP-certified vendor
• Pre-shipment Quality Control (QC) checklist introduced for all kits
• Site training program on kit inspection upon delivery
• Deviation log created to analyze root causes and frequency trends

The CAPA was reviewed and accepted by the EMA without further observations in the subsequent audit.

Sample Collection Logistics: Temperature and Timeliness

Clinical samples—especially labile analytes such as cytokines, RNA, or PBMCs—must be shipped within specific time and temperature ranges. Sponsors should:

• Define acceptable hold times post-collection
• Use temperature data loggers in shipments
• Employ validated packaging materials (e.g., TempTale, NanoCool)
• Provide clear SOPs for weekend/holiday shipments

Sample Kit Reconciliation Process

Reconciliation involves verifying that the number of kits sent matches the number of samples collected and returned. This should be:

• Tracked in an electronic laboratory information management system (LIMS)
• Documented in the Sample Accountability Log
• Cross-checked by monitors during SDV visits
• Reviewed monthly by QA for trends or recurring errors

Table: Sample Logistics Compliance Checklist

Training and Oversight Responsibilities

Sponsors must ensure all site personnel receive training on:

• Kit component identification and usage
• Cold chain procedures
• Use of return shipping documents
• How to report and manage kit issues

Training should be logged and reviewed as part of inspection readiness audits.

Reference to Public Registry

For examples of trials implementing centralized kit logistics, see studies listed in the Australian New Zealand Clinical Trials Registry (ANZCTR).

Conclusion

Sample collection kits and logistics are no longer just operational tasks—they are core compliance areas evaluated during regulatory inspections. By applying standardized kit design, validated logistics processes, and thorough staff training, sponsors can ensure sample integrity, minimize deviations, and demonstrate control under both FDA and EMA oversight. A proactive CAPA framework ensures issues are identified and resolved before they compromise data or compliance.